Product Description
Mechanisms of Action: VMAT1 Inhibitor, NIACR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral, Sublingual
FDA Designation: *
Approval Status: Not Approved
Approved Countries: China | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Yaupon
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Attention Deficit Disorder with Hyperactivity
Phase 1: Amphetamine-Related Disorders|Methamphetamine Dependence
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00100074 |
NIDA-CPU-0007-1 | P1 |
Unknown status |
Amphetamine-Related Disorders |
None |
2019-03-21 |
Treatments |
|
NCT00439504 |
NIDA-CPU-0012-1 | P1 |
Unknown status |
Amphetamine-Related Disorders|Methamphetamine Dependence |
None |
2019-03-21 |
Treatments |
|
NCT00519259 |
NIDA-CPU-0009-1 | P1 |
Unknown status |
Methamphetamine Dependence|Amphetamine-Related Disorders |
None |
2019-03-21 |
Treatments |
|
NCT00664703 |
R43MH081553 | P2 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2010-01-01 |
2019-03-18 |